1-11 of 11
Steven T. Rosen, MD, FRCPA
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Multicenter Phase II Study Of Bortezomib (VELCADE®) Combined With Rituximab For Untreated High Tumor Burden (HTB) Indolent Non-Hodgkin Lymphoma (NHL): Long-Term Follow-Up Of Outcomes and Examination Of Prognostic Factors

Andrew M Evens, DO, MSc, Mitchell R Smith, MD, PhD, Izidore S Lossos, MD, Irene Helenowski, PhD, Michael Millenson, MD, Jane N. Winter, MD, Steven T. Rosen, MD, FRCPA, Leo I. Gordon, MD
Journal: Blood
Blood (2013) 122 (21): 1807.
https://doi.org/10.1182/blood.V122.21.1807.1807
Published: 2013
Journal Articles

Targeting Glucose Metabolism and Compensatory Metabolic Resistance in Chronic Lymphocytic Leukemia

Kehinde U.A. Adekola, MBBS, Vivian Liu, Shuo Ma, MD, PhD, Steven T. Rosen, MD, FRCPA, Mala Shanmugam, PhD
Journal: Blood
Blood (2012) 120 (21): 1801.
https://doi.org/10.1182/blood.V120.21.1801.1801
Published: 2012
Journal Articles

A Multicenter Phase II Clinical Trial of Rituximab Combined with Bortezomib (VELCADE®) Therapy for Untreated “High Tumor Burden” Indolent Non-Hodgkin Lymphoma (NHL)

Andrew M. Evens, DO, MSc, Mitchell R Smith, MD, PhD, Izidore S Lossos, MD, Borko Jovanovic, PhD, Adam Cohen, MD, Jane N. Winter, MD, Steven T. Rosen, MD, FRCPA, Leo I. Gordon, MD
Journal: Blood
Blood (2012) 120 (21): 1642.
https://doi.org/10.1182/blood.V120.21.1642.1642
Published: 2012
Journal Articles

Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE): First Detailed Report of Primary Treatment

Francine M. Foss, MD, Kenneth R. Carson, MD, Lauren Pinter-Brown, MD, Steven M. Horwitz, MD, Steven T. Rosen, MD, FRCPA, Barbara Pro, MD, Massimo Federico, MD, Christian Gisselbrecht, MD, Eric D. Hsi, MD
Journal: Blood
Blood (2012) 120 (21): 1614.
https://doi.org/10.1182/blood.V120.21.1614.1614
Published: 2012
Journal Articles

Biomarker Quality Assurance (QA) Findings From the Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE) Registry

Eric D. Hsi, MD, Aaron M. Gruver, MD, PhD, Francine M. Foss, MD, Kenneth R. Carson, MD, Lauren Pinter-Brown, MD, Steven M. Horwitz, MD, Steven T. Rosen, MD, FRCPA, Barbara Pro, MD, Massimo Federico, MD, Christian Gisselbrecht, MD
Journal: Blood
Blood (2012) 120 (21): 4263.
https://doi.org/10.1182/blood.V120.21.4263.4263
Published: 2012
Journal Articles

Targeting Glycolysis and Compensatory Mitochondrial Metabolism in Multiple Myeloma with FDA Approved Ritonavir and Metformin Via Synthetic Lethality

Kehinde U. A. Adekola, M.B.B.S, Maylyn Martinez, Steven T. Rosen, MD, FRCPA, Mala Shanmugam, PhD
Journal: Blood
Blood (2012) 120 (21): 4016.
https://doi.org/10.1182/blood.V120.21.4016.4016
Published: 2012
Journal Articles

Survival of Newly Diagnosed T-Cell Lymphoma (TCL) in the Modern Era: Investigation of Prognostic Factors with Critical Examination of Therapy in a Multicenter US Cohort.

Andrew M. Evens, DO, MSc, Tatyana Feldman, MD, Aimee Kroll, MS, Lori S. Muffly, MD, Eric Winer, MD, Christopher Flowers, MD, Frederick Lansigan, MD, Chadi Nabhan, MD, FACP, Loretta Nastoupil, MD, Austin Kim, MD, Xiuning Li, MD, Kathryn Waksmundzki, David Lam, MD, Jacqueline Tessa Draper, BS, Ashley Meilleur, BS, Rajneesh Nath, MD, Peter Cygan, MD, Jorge J Castillo, MD, Andre Goy, MD, Bruce Woda, MD, Sonali M. Smith, MD, Steven T. Rosen, MD, FRCPA, Jeremy S. Abramson, MD
Journal: Blood
Blood (2012) 120 (21): 2728.
https://doi.org/10.1182/blood.V120.21.2728.2728
Published: 2012
Journal Articles

A Phase 1b/2 Study of Prolonged Infusion Carfilzomib in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma: Updated Efficacy and Tolerability From the Completed 20/56mg/m 2 Expansion Cohort of PX-171-007

Kyriakos P Papadopoulos, MD, Peter Lee, MD, PhD, Seema Singhal, MD, Joseph R. Holahan, MD, David H. Vesole, MD, PhD, Steven T. Rosen, MD, FRCPA, Lori Kunkel, MD, Alison L. Hannah, MD, David S. Siegel, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 2930.
https://doi.org/10.1182/blood.V118.21.2930.2930
Published: 2011
Journal Articles

Myeloma Exhibits Dependence on Atypical Glucose Transporters: Targeting MCL-1 Through GLUT4 Inhibition

Mala Shanmugam, PhD, Javelin C Cheng, MS, Samuel K McBrayer, Steven T. Rosen, MD, FRCPA
Journal: Blood
Blood (2011) 118 (21): 1850.
https://doi.org/10.1182/blood.V118.21.1850.1850
Published: 2011
Journal Articles

A Phase I/II Trial of Combination Gemcitabine and Bortezomib (VELCADE®) for Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma (NHL) and Aggressive B-Cell NHL

Andrew M. Evens, DO, MSc, Steven T. Rosen, MD, FRCPA, Leo I. Gordon, MD, FACP, Irene Helenowski, MS, Justin Kline, MD, Annette Larsen, B.A., R.N., Jane N. Winter, M.D., Sonali M. Smith, MD, Koen M. Van Besien, MD
Journal: Blood
Blood (2011) 118 (21): 1646.
https://doi.org/10.1182/blood.V118.21.1646.1646
Published: 2011
Journal Articles

Predictors of Response to Salvage Therapy for Advanced Chronic Lymphocytic Leukemia (ECOG Protocol 2903)

Neil E. Kay, Haesook Kim, PhD, Sanford Kempin, MD, Steven T. Rosen, MD, FRCPA, Hillard Lazarus, Diane F. Jelinek, PhD, Martin S. Tallman, MD
Journal: Blood
Blood (2010) 116 (21): 2463.
https://doi.org/10.1182/blood.V116.21.2463.2463
Published: 2010